Robust Pipeline

Our pipeline includes five core development programs. We intend to initiate our FDA cleared clinical trials for Long COVID and PTHS in 2023 pending receipt of sufficient funding. In addition, we are also currently focused on our pre-clinical development programs for multiple sclerosis (“MS”) and Lupus/systemic lupus erythematosus (“SLE”). We plan to submit two additional IND applications to the FDA to initiate Phase 1/2a clinical trials to assess the safety and efficacy of AlloRx Stem Cell therapy in adults with Lupus (SLE) in 2023 and in adults with MS in late 2023 or 2024, which will be subject to FDA clearance prior to the initiation of any clinical trials for these indications.

Our development programs are illustrated in the pipeline chart below, including the Phase 1/2a clinical trials for PTHS and Long COVID (PASC):